MeSH tree: D03.383.742.680.245.500.775
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic ...
Aug 5, 2026
0
34
The need for more effective lung cancer treatments is paramount, as the disease remains a leading cause of cancer deaths in the United States. New findings by a research team from the Stony Brook Cancer Center highlight a ...
Aug 4, 2026
0
6
Researchers at National Taiwan University refined a pseudo-germ-free mouse model to make gut microbiome studies safer for mice and more reliable. Using this model, they found that antibiotic-driven changes in gut microbes ...
Jun 12, 2026
0
9
A national team of cancer researchers led by Drs. Kenneth Shroyer and Natalia Marchenko at Stony Brook Medicine, and Dr. Luisa Escobar-Hoyos of Yale School of Medicine, investigated the role of Keratin 17 (K17) in the most ...
May 20, 2026
0
8
Chemotherapy can be life-saving for many patients, but not all tumors respond—and some that do, may eventually become resistant. Investigators at Houston Methodist have identified a possible explanation for this resistance, ...
May 18, 2026
0
9
A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after tumors have already spread ...
Apr 22, 2026
0
10
A new study in mice hints at the potential to use tiny particles made with RNA molecules to deliver chemotherapy drugs and other therapies directly to tumors, killing cancer cells without generating an immune response or ...
Feb 6, 2026
0
117
A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women facing platinum-resistant ovarian cancer (PROC). Researchers evaluated a novel DNA-based therapy, Elenagen, ...
Jan 12, 2026
0
14
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in a phase 2 clinical trial for individuals with high-risk non-muscle-invasive bladder cancer whose cancer had previously resisted treatment.
Aug 13, 2025
0
53
When low doses of cancer drugs are administered continuously near malignant brain tumors using so-called iontronic technology, cancer cell growth drastically decreases. Researchers at Linköping University, Sweden, and the ...
Jun 19, 2024
0
30
